Cerebrolysin vs IGF-1 LR3
Well Studied vs limited
monitor Researched · 90% Additive neurotrophic pathway effects.
Molecular Data
Cerebrolysin IGF-1 LR3
Weight Variable —
Half-life Minutes (component-dependent; e.g., BDNF ~10 min) 20-30 hours
Chain Multiple peptides 83 amino acids
Type Purified porcine brain proteins Synthetic IGF-1 analog
Key Benefits
Cerebrolysin
01 Direct brain delivery
02 Standardized dosing
03 Extensive clinical evidence
04 Ready-to-use formulation
05 Used clinically in 50+ countries
IGF-1 LR3
01 Approximately 3x more potent than native IGF-1
02 Promotes muscle hypertrophy and hyperplasia in animal models
03 15-20% lean mass gains observed in 4-week rat studies
04 Anti-catabolic effects preserve muscle during cachexia
05 20-30 hour half-life for sustained effects
Dosing Protocols
Cerebrolysin
10-50mL depending on indication (stroke/TBI higher doses) / Once daily for acute conditions; 5 days weekly for chronic conditions
Small Volume IV Up to 10mL Once daily
Intramuscular Up to 5mL Once daily
Acute Stroke 20-50mL Once daily for 10-21 days
Traumatic Brain Injury 20-50mL Once daily for 7-30 days
Alzheimer's Disease 10-30mL 5 days weekly for 4 weeks
Vascular Dementia 10-30mL 5 days weekly for 4 weeks
IGF-1 LR3
20-100 mcg daily (start low at 20-30 mcg) / Once daily, or split AM/PM for higher doses
Beginner Protocol 20-30mcg Once daily post-workout
Intermediate 40-60mcg Once daily
Advanced 80-100mcg Once or split AM/PM
Women's Protocol 10-20mcg Once daily
Side Effects
Cerebrolysin
Generally well tolerated
Possible mild dizziness or agitation in early treatment
IGF-1 LR3
Hypoglycemia (lasting up to 30 hours) - CRITICAL
Water retention
Joint stiffness
Muscle soreness
Increased pump during workouts
Contraindications
Epilepsy
Severe renal insufficiency
History of severe allergic reactions to porcine products
NEVER approved for human use - research chemical only
Cancer history or undiagnosed growths
May cause organ hypertrophy (heart, intestines)
WADA prohibited - causes failed drug tests
Research Evidence
Cerebrolysin IGF-1 LR3
Status Well Studied limited
References 5 studies 4 studies
Latest 2021 November 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.